ReviewInternational journal of neonatal screening2018
Newborn Screening for Sickle Cell Disease: Indian Experience.
Review in International journal of neonatal screening, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- "If People Know, They Will Think Something Is Wrong with Me": An Ethnography of Sickle Cell Hemoglobinopathy, Stigma, and Health Disparities in Tribal Odisha, India.Journal of racial and ethnic health disparities · 2026Article
- Birth Prevalence of Sickle Cell Disease in India: A Systematic Review and Meta-Analysis.International journal of neonatal screening · 2026Review
- Newborn Screening for Hemoglobinopathies and Thalassemias: Brief History, Recent Activities, and Global Status-2026.International journal of neonatal screening · 2026Review
- Sickle cell disease screening: Experiences of parents with positive newborns at Korle Bu TeachingHospital.PloS one · 2026Article
- Cord Blood-Based Neonatal Screening for Hemoglobinopathies in Northern Tunisia.International journal of neonatal screening · 2025Article
- Barriers, facilitators and recommendations for the implementation of newborn sickle cell screening program in tribal communities: findings from a qualitative multicentric study in India.The Lancet regional health. Southeast Asia · 2025Article
- A Delphi study to identify and prioritize research areas in sickle cell disease in India.Scientific reports · 2025Article
- Socioeconomic health and impact of sickle cell disease and vaso-occlusive crises in India: results from B-VOCAL study.BMJ global health · 2025Observational
- Unveiling the Burden of Sickle Cell Anemia: A Pilot Study Validating Dried Blood Spots for Newborn Screening.Indian journal of pediatrics · 2025Article
- Sickle cell disease in India: the journey and hope for the future.Hematology. American Society of Hematology. Education Program · 2024Review
- Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.The Lancet. Haematology · 2023Review
- Maternal mortality among women with sickle cell disease in Jamaica over two decades (1998-2017).EClinicalMedicine · 2022Article
- Sickle cell disease in India: a scoping review from a health systems perspective to identify an agenda for research and action.BMJ global health · 2021Article
- Haemoglobinopathies in India: estimates of blood requirements and treatment costs for the decade 2017-2026.Journal of community genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD) is a major public health problem in India with the highest prevalence amongst the tribal and some non-tribal ethnic groups. The clinical manifestations are extremely variable ranging from a severe to mild or asymptomatic condition. Early diagnosis and providing care is critical in SCD because of the possibility of lethal complications in early infancy in pre-symptomatic children. Since 2010, neonatal screening programs for SCD have been initiated in a few states of India. A total of 18,003 babies have been screened by automated HPLC using either cord blood samples or heel prick dried blood spots and 2944 and 300 babies were diagnosed as sickle cell carriers and SCD respectively. A follow up of the SCD babies showed considerable variation in the clinical presentation in different population groups, the disease being more severe among non-tribal babies. Around 30% of babies developed serious complications within the first 2 to 2.6 years of life. These pilot studies have demonstrated the feasibility of undertaking newborn screening programs for SCD even in rural areas. A longer follow up of these babies is required and it is important to establish a national newborn screening program for SCD in all of the states where the frequency of the sickle cell gene is very high followed by the development of comprehensive care centers along with counselling and treatment facilities. This comprehensive data will ultimately help us to understand the natural history of SCD in India and also help the Government to formulate strategies for the management and prevention of sickle cell disease in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.